Suprax Articles
Mylan debuts generic Antara; FDA approves generics of Actavis' Suboxone, Lupin's Suprax and Zydus' Zantac
25 February 2013
13.7% growth for Indian pharma recorded 13.7%to $9.43 billion in first three quarters of fiscal 2009-10
4 February 2010
India's Lupin in US marketing deal for Suprax
30 June 2008
Cornerstone and Lupin in Suprax deal
7 February 2005
Lupin launches oral generic cefixime in USA
19 April 2004
Lupin gets US ANDA for cefixime suspension
15 March 2004
Lupin to launch cefixime in USA
16 June 2003
Fujisawa and Elder sign marketing pact
2 March 2000
Net Loss Plunges To $270 Million At Fujisawa
21 May 1998
New Data With Glaxo Wellcome's Raxar
9 June 1997
Fujisawa Sees 31% Net Income Rise For FY1996
26 May 1997
Japan's Fujisawa Looks To 21 Century Growth
16 October 1995
Fujisawa Net Down Though Operating Income Soars
29 May 1995
US PRODUCT NEWS IN BRIEF
18 April 1994
JAPAN DRUGMAKERS' FOREIGN SALES STILL LOW
26 July 1993
PEDIATRIC CEFZON LAUNCHED IN JAPAN
14 June 1993
FUJISAWA'S PROMISING R&D PIPELINE
9 November 1992
FUJISAWA HIT BY JAPAN DRUG PRICING MOVES
1 June 1992
FUJISAWA TAIWAN PLANT PLANNED
13 April 1992
FUJISAWA TAIWAN PLANT PLANNED
13 April 1992
FUJISAWA KOREA JV COMPLETED
9 March 1992
FUJISAWA'S CEFZON LAUNCHED IN JAPAN
6 January 1992
Showing 1-24 of 24 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
